Patents Assigned to JCR Pharmaceuticals Co., Ltd.
  • Patent number: 11046751
    Abstract: Disclosed are a human serum albumin mutant that can be linked to a physiologically active protein to increase the stability of the protein in the blood, as well as a resulting protein produced by linking with the mutant. The protein produced by linking with the mutant consists of a human serum albumin mutant comprising the amino acid sequence set forth as SEQ ID NO:3 or an amino acid sequence that, in comparison with it, lacks not more than 10 amino acid residues and/or has not more than 10 amino acid residues replaced, with the proviso that the asparagine residue occurring at position 318 and the threonine at position 320 from the N-terminus of the amino acid sequence set forth as SEQ ID NO:3 are preserved and linked by peptide bonds via a single amino acid residue (X) except proline placed between those two amino acid residues, and a physiologically active protein linked to the mutant.
    Type: Grant
    Filed: April 10, 2020
    Date of Patent: June 29, 2021
    Assignee: JCR PHARMACEUTICALS CO., LTD.
    Inventors: Kenichi Takahashi, Aya Yoshioka, Hideto Morimoto, Masafumi Kinoshita
  • Publication number: 20210187082
    Abstract: [Problem] To provide a pharmaceutical composition containing a fusion protein comprising an antibody and a lysosomal enzyme as an active ingredient, which is stable enough to permit its distribution to the market. [Solution] A lyophilized formulation containing; a fusion protein comprising an antibody and a lysosomal enzyme as an active ingredient, and further containing a neutral salt, a disaccharide, a nonionic surfactant, and a buffer. Such a lyophilized formulation includes, for example, as an active ingredient, a fusion protein comprising an anti-transferrin receptor antibody and human iduronate-2-sulfatase, and further containing sodium chloride as the neutral salt, sucrose as the disaccharide, poloxamer as the nonionic surfactant, and phosphate buffer as the buffer.
    Type: Application
    Filed: February 22, 2021
    Publication date: June 24, 2021
    Applicant: JCR Pharmaceuticals Co., Ltd.
    Inventors: Hidehito Yasukawa, Yuka Yamaguchi, Shinji Okabe
  • Publication number: 20210171561
    Abstract: Disclosed is a method for decomposing chondroitin sulfate contained in a sample into disaccharide. In particular disclosed is a method for decomposing chondroitin sulfate contained in a sample into disaccharide by heating the chondroitin sulfate in HCl-methanol containing 2,2-dimethoxypropane at a temperature of 60° C. to 90° C. for 50 minutes to 180 minutes, optionally in the method, the sample is selected from body fluid, a cell, a tissue, an organ, a cell culture solution, a tissue culture solution, a food, and a feed, or a derived therefrom.
    Type: Application
    Filed: February 22, 2021
    Publication date: June 10, 2021
    Applicant: JCR Pharmaceuticals Co., Ltd.
    Inventors: Noboru TANAKA, Sachiho KIDA
  • Publication number: 20210132040
    Abstract: A method for decomposing dermatan sulfate and heparan sulfate contained in a sample into a disaccharide, respectively, wherein the dermatan sulfate is decomposed into a disaccharide in which a uronic acid and an amino sugar are joined with an ?-1,3 bond, and the heparan sulfate is decomposed into the disaccharide in which the uronic acid and the amino sugar are joined with the ?-1,4 bond, and wherein, the dermatane sulfate is decomposed by heating in hydrogen chloride methanol solution containing 2,2-dimethoxypropane, at a temperature of 60 to 80° C., and for 20 to 100 minutes, and the heparan sulfate is decomposed by heating in hydrogen chloride methanol solution containing 2,2-dimethoxypropane, for 80 to 180 minutes, and at a temperature of 65 to 85° C.
    Type: Application
    Filed: February 20, 2018
    Publication date: May 6, 2021
    Applicant: JCR PHARMACEUTICALS CO., LTD.
    Inventors: Noboru TANAKA, Sachiho KIDA
  • Publication number: 20210104046
    Abstract: Disclosed are a software for analyzing images of a fertilized egg, the software providing a means for executing a process including: (a) a step of measuring the difference in area between the female pronucleus and the male pronucleus from images of a fertilized egg obtained in a period of 1 to 10 hours before the time of occurrence of male and female pronuclear membrane breakdown as a reference; (b) a step of measuring the difference in are between the female pronucleus and the male pronucleus from images of the fertilized egg obtained immediately before the time of occurrence of male and female pronuclear membrane breakdown as the reference; and (c) a step of storing the measured values of the area difference obtained in the step (a) and the area difference obtained in the step (b), to be readable at any time as needed, and an apparatus incorporating this software.
    Type: Application
    Filed: December 17, 2020
    Publication date: April 8, 2021
    Applicant: JCR Pharmaceuticals Co., Ltd.
    Inventors: Masahide SHIOTANI, Junko OTSUKI
  • Patent number: 10968267
    Abstract: Disclosed is a medicine containing a long-lasting human growth hormone preparation as an active ingredient, which has low prolactin-like activity and shows long half-life in blood as compared with 22K human growth hormone. The long-lasting human growth hormone includes a fusion protein exhibiting growth-promoting activity and having a human serum albumin part and a 20K human growth hormone part, particularly a fusion protein in which the 20K human growth hormone part is linked to C-terminus of the human serum albumin part via a linker sequence.
    Type: Grant
    Filed: September 14, 2018
    Date of Patent: April 6, 2021
    Assignee: JCR PHARMACEUTICALS CO., LTD.
    Inventors: Kenichi Takahashi, Aya Yoshioka, Yuri Koshimura
  • Patent number: 10940185
    Abstract: [Problem] To provide a pharmaceutical composition containing a fusion protein comprising an antibody and a lysosomal enzyme as an active ingredient, which is stable enough to permit its distribution to the market. [Solution] A lyophilized formulation containing; a fusion protein comprising an antibody and a lysosomal enzyme as an active ingredient, and further containing a neutral salt, a disaccharide, a nonionic surfactant, and a buffer. Such a lyophilized formulation includes, for example, as an active ingredient, a fusion protein comprising an anti-transferrin receptor antibody and human iduronate-2-sulfatase, and further containing sodium chloride as the neutral salt, sucrose as the disaccharide, poloxamer as the nonionic surfactant, and phosphate buffer as the buffer.
    Type: Grant
    Filed: December 28, 2017
    Date of Patent: March 9, 2021
    Assignee: JCR Pharmaceuticals Co., Ltd.
    Inventors: Hidehito Yasukawa, Yuka Yamaguchi, Shinji Okabe
  • Publication number: 20210061918
    Abstract: Aqueous pharmaceutical compositions containing a fusion protein of an antibody and a lysosomal enzyme as an active ingredient, which are stable enough to be marketed, are disclosed. The aqueous pharmaceutical composition, for example, comprises the fusion protein of the antibody and the lysosomal enzyme at a concentration of 0.5 to 20 mg/mL, sodium chloride at a concentration of 0.3 to 1.2 mg/mL, sucrose at a concentration of 50 to 100 mg/mL, a nonionic surfactant at a concentration of 0.15 to 3 mg/mL, a buffer at a concentration of 3 to 30 mM, and is adjusted to pH 5.0 to 7.5.
    Type: Application
    Filed: September 7, 2018
    Publication date: March 4, 2021
    Applicant: JCR Pharmaceuticals Co., Ltd.
    Inventors: Hidehito YASUKAWA, Yuka YAMAGUCHI, Shinji OKABE
  • Publication number: 20210038739
    Abstract: [Problems] To provide a technique for efficiently incorporating an agent having to function in muscle tissue, which is not sufficiently incorporated into muscle tissue when administered in body, into muscle tissue, particularly muscle tissue composed of skeletal muscle or cardiac muscle. [Solution] A conjugate of an anti-human transferrin receptor antibody and an agent, wherein the agent is a biologically active agent that should function in muscle tissue, e.g., a lysosomal enzyme such as acid ?-glucosidase, ?-galactosidase A.
    Type: Application
    Filed: February 5, 2019
    Publication date: February 11, 2021
    Applicant: JCR Pharmaceuticals Co., Ltd.
    Inventors: Kenichi Takahashi, Hiroyuki Sonoda
  • Publication number: 20200406229
    Abstract: A chromatography column for the use of separation of acidic sugar chains, wherein the column comprises a first column and a second column, the second column connected by a flow path downstream of an outlet of the first column, and selected from the following (1) or (2): (1) the carrier of the first column is hydrophobically modified silica having a group containing a primary amine, a secondary amine or/and a tertiary amine, and the carrier of the second column is a resin having a group containing a primary amine, a secondary amine or/and a tertiary amine; (2) the carrier of the first column is a resin having a group containing a primary amine, a secondary amine or/and a tertiary amine, and the carrier of the second column is hydrophobically modified silica having a group containing a primary amine, a secondary amine, or/and a tertiary amine.
    Type: Application
    Filed: November 14, 2018
    Publication date: December 31, 2020
    Applicant: JCR Pharmaceuticals Co., Ltd.
    Inventors: Tomoki FUKATSU, Chika MOROOKA
  • Publication number: 20200384061
    Abstract: The present invention provides a fusion protein of BDNF and an anti-human transferrin receptor antibody, in which in a heavy chain variable region of the antibody, (a) CDR1 includes an amino acid sequence of SEQ ID NO: 66 or SEQ ID NO: 67, (b) CDR2 includes an amino acid sequence of SEQ ID NO: 13 or SEQ ID NO: 14, and (c) CDR3 includes an amino acid sequence of SEQ ID NO: 15 or SEQ ID NO: 16.
    Type: Application
    Filed: December 26, 2017
    Publication date: December 10, 2020
    Applicant: JCR Pharmaceuticals Co., Ltd.
    Inventors: Hiroyuki Sonoda, Kenichi Takahashi
  • Patent number: 10858640
    Abstract: Disclosed is a method for production of recombinant human DNase I which is of such high purity as may be directly used as a medical drug. The method includes the steps of; culturing recombinant DNase I-producing mammalian cells, subjecting a culture supernatant to an anion-exchange column chromatography, subjecting to a column chromatography employing as solid phase a material having affinity for phosphate group, subjecting to a cation-exchange column chromatography, and subjecting to a dye affinity column chromatography.
    Type: Grant
    Filed: April 28, 2017
    Date of Patent: December 8, 2020
    Assignee: JCR PHARMACEUTICALS CO., LTD.
    Inventors: Yuri Koshimura, Miroslav Matev, Hiroyuki Sonoda
  • Publication number: 20200317798
    Abstract: Provided is an anti-human transferrin receptor antibody or an analog thereof, wherein in the heavy chain variable region of the antibody, (a) CDR1 comprises the amino acid sequence set forth as SEQ ID NO: 62 or SEQ ID NO: 63, (b) CDR2 comprises the amino acid sequence set forth as SEQ ID NO: 13 or SEQ ID NO: 14, and (c) CDR3 comprises the amino acid sequence set forth as SEQ ID NO: 15 or SEQ ID NO: 16, and an analogue thereof.
    Type: Application
    Filed: June 23, 2020
    Publication date: October 8, 2020
    Applicant: JCR Pharmaceuticals Co., Ltd.
    Inventors: Hiroyuki Sonoda, Kenichi Takahashi
  • Patent number: 10759749
    Abstract: A nobel therapeutic agent for diabetes which can suppress occurrence of side effects such as persistent hypoglycemia is provided. The active ingredient is a derivative of 1,1-diphenylsemicarbazide or 1,1-diphenylthiosemicarbazide. In particular, the active ingredient is a derivative of 1,1-diphenyl-4-cyclohexyl-semicarbazide or 1,1-diphenyl-4-cyclohexyl-thiosemicarbazide exhibiting hypoglycemic action when orally administered.
    Type: Grant
    Filed: August 28, 2017
    Date of Patent: September 1, 2020
    Assignees: JCR Pharmaceuticals Co., Ltd., National University Corporation Kone University, National University Corporation Chiba University
    Inventors: Susumu Seino, Kenji Sugawara, Ichiro Mori, Akio Matsumoto, Yoshie Reien
  • Patent number: 10759864
    Abstract: Provided is an anti-human transferrin receptor antibody or an analog thereof, wherein in the heavy chain variable region of the antibody, (a) CDR1 comprises the amino acid sequence set forth as SEQ ID NO: 62 or SEQ ID NO: 63, (b) CDR2 comprises the amino acid sequence set forth as SEQ ID NO: 13 or SEQ ID NO: 14, and (c) CDR3 comprises the amino acid sequence set forth as SEQ ID NO: 15 or SEQ ID NO: 16, and an analogue thereof.
    Type: Grant
    Filed: December 26, 2017
    Date of Patent: September 1, 2020
    Assignee: JCR Pharmaceuticals Co., Ltd.
    Inventors: Hiroyuki Sonoda, Kenichi Takahashi
  • Patent number: 10654912
    Abstract: Disclosed are a human serum albumin mutant that can be linked to a physiologically active protein to increase the stability of the protein in the blood, as well as a resulting protein produced by linking with the mutant. The protein produced by linking with the mutant consists of a human serum albumin mutant comprising the amino acid sequence set forth as SEQ ID NO:3 or an amino acid sequence that, in comparison with it, lacks not more than 10 amino acid residues and/or has not more than 10 amino acid residues replaced, with the proviso that the asparagine residue occurring at position 318 and the threonine at position 320 from the N-terminus of the amino acid sequence set forth as SEQ ID NO:3 are preserved and linked by peptide bonds via a single amino acid residue (X) except proline placed between those two amino acid residues, and a physiologically active protein linked to the mutant.
    Type: Grant
    Filed: September 8, 2016
    Date of Patent: May 19, 2020
    Assignee: JCR PHARMACEUTICALS CO., LTD.
    Inventors: Kenichi Takahashi, Aya Yoshioka, Hideto Morimoto, Masafumi Kinoshita
  • Patent number: 10604779
    Abstract: Disclosed is a highly efficient method for production of highly pure mutant-type human erythropoietin. The method is for production of mutant-type human erythropoietin, in which a transformed mammalian cell is allowed to produce the mutant-type human erythropoietin, and the supernatant of the culture is subjected to hydrophobic column chromatography, multimodal anion exchange column chromatography, anion exchange column chromatography, phosphate group affinity column chromatography, and gel filtration column chromatography, in this order.
    Type: Grant
    Filed: March 7, 2017
    Date of Patent: March 31, 2020
    Assignee: JCR PHARMACEUTICALS CO., LTD.
    Inventors: Shinji Kakimoto, Miroslav Matev, Tsuyoshi Fukui, Yukichi Hatano, Junya Tani, Kazutoshi Mihara, Kenichi Takahashi, Atsushi Sugimura
  • Patent number: 10557115
    Abstract: Provided are a novel medium for expressing glycoproteins by culturing cells and a method for producing glycoproteins by culturing cells in the medium. Further provided are a medium comprising uridine and N-acetyl-D-mannosamine for the use of expression of a glycoprotein by culturing cells and a method for producing glycoproteins by culturing cells in for medium.
    Type: Grant
    Filed: March 26, 2019
    Date of Patent: February 11, 2020
    Assignee: JCR Pharmaceuticals Co., Ltd.
    Inventors: Miroslav Matev, Kenichi Takahashi, Shinji Kakimoto, Ayaka Kotani
  • Publication number: 20190352599
    Abstract: Provided are a novel medium for expressing glycoproteins by culturing cells and a method for producing glycoproteins by culturing cells in said medium. Further provided are a medium comprising uridine and N-acetyl-D-mannosamine for the use of expression of a glycoprotein by culturing cells and a method for producing glycoproteins by culturing cells in said medium.
    Type: Application
    Filed: March 26, 2019
    Publication date: November 21, 2019
    Applicant: JCR Pharmaceuticals Co., Ltd.
    Inventors: Miroslav MATEV, Kenichi Takahashi, Shinji Kakimoto, Ayaka Kotani
  • Publication number: 20190338043
    Abstract: Provided is an anti-human transferrin receptor antibody or an analog thereof, wherein in the heavy chain variable region of the antibody, (a) CDR1 comprises the amino acid sequence set forth as SEQ ID NO: 62 or SEQ ID NO: 63, (b) CDR2 comprises the amino acid sequence set forth as SEQ ID NO: 13 or SEQ ID NO: 14, and (c) CDR3 comprises the amino acid sequence set forth as SEQ ID NO: 15 or SEQ ID NO: 16, and an analogue thereof.
    Type: Application
    Filed: December 26, 2017
    Publication date: November 7, 2019
    Applicant: JCR Pharmaceuticals Co., Ltd.
    Inventors: Hiroyuki Sonoda, Kenichi Takahashi